Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology...

Particle Sciences and Microfluidics Collaborate to Share Formulation and
Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis
and Commercialization

BETHLEHEM, Pa. and NEWTON, Mass., June 30 /PRNewswire/ -- Microfluidics, a
wholly owned subsidiary of Microfluidics International Corporation (OTC
Bulletin Board: MFLU), and Particle Sciences Inc. (PSI) have formed a
strategic alliance to help biopharmaceutical companies leverage the most
advanced and reliable nanotechnology and formulation methods available to
develop, analyze and commercialize Active Pharmaceutical Ingredients (APIs).

Particle Sciences is a leading Contract Research Organization (CRO) founded in
1991 with a unique specialization in formulation/delivery, analytic services
and clinical trial material (CTM) production. With over 35 scientists holding
more than 100 patents, a comprehensive formulations laboratory, cGMP
production suites and cGMP analytical/bioanalytical capabilities, Particle
Sciences has a solid track record of developing commercializable technologies
for companies ranging from early venture-backed to large pharma.

According to Robert W. Lee, Ph.D., Vice President of Pharmaceutical
Development at Particle Sciences, "We are solution oriented and not married to
a specific platform. Our model is to offer our clients a number of
state-of-the-art approaches using best-of-breed, reproducible and scalable
technologies. Delivery formats range from solid solutions and combination
products to particle suspensions and emulsions. For high shear fluid
processing, we settled on the Microfluidizer(R) after a thorough evaluation of
the competing alternatives. One area of interest to PSI is adding the
Microfluidizer processor to its existing approaches for particle size
reduction of poorly water-soluble APIs to the submicron range, which is an
increasingly important formulation approach for pharmaceutical API
development."

Microfluidizer high shear fluid processors deliver unsurpassed results in
uniform and scalable top-down particle size reduction to over 1,100
biopharmaceutical companies worldwide. Combining 25 years of proven processing
success with PSI's experience creates a uniquely comprehensive solution
portfolio for the Company's pharmaceutical clients. In addition, Microfluidics
Reaction Technology (MRT), an innovative technique for bottom-up nanoparticle
creation and nanoencapsulation via continuous crystallization and chemical
reactions, offers even more possibilities in novel drug development and will
also be incorporated into PSI's offerings.

As part of the non-exclusive agreement, Particle Sciences has installed an
M-110EH-30 Basic BioPharma Microfluidizer processor ideal for nanoemulsions,
nanosuspensions, cell disruption and nanoencapsulation in pilot and production
volumes.

"We believe Microfluidizer processors are the undisputed gold standard in the
pharmaceutical industry, from the lab to clinical research and production,"
said Bill Kober, Vice President of Sales, Americas, at Microfluidics. "With
several well-known drugs on the market, customers use our processors to reduce
particle sizes uniformly, improve bioavailability and target drug delivery.
Through this relationship, our users now have access to our technology
combined with the scientific ingenuity and experience of Particle Sciences. We
are excited to provide a uniquely complete portfolio of solutions for global
API research and development."

About Microfluidics
Microfluidics, a wholly owned subsidiary of Microfluidics International
Corporation, is a supplier of advanced fluid processing equipment and reaction
technology for laboratory, pilot scale and manufacturing applications. The
equipment enables the formulation and manufacture of numerous nanomaterials
and nanoscale products and produces the most uniform and smallest liquid and
suspended solid particles available. Microfluidics has been a worldwide
supplier of Microfluidizer(R) high shear fluid processing systems to the
biotechnology, pharmaceutical, chemical and cosmetics industries since 1984.
As a leader in the field, Microfluidics has enabled numerous companies and
institutions to formulate, validate and produce licensed drugs for the
worldwide healthcare market. Companies seeking to produce
difficult-to-formulate products or to find better methods of bio-processing
can take advantage of complimentary sample testing at any of three
Microfluidics facilities. Visit www.microfluidicscorp.com, email
mixinginfo@mfics.com or contact Microfluidics at (800) 370-5452 for
application information.

About Particle Sciences

Particle Sciences is an integrated provider of drug development services.
Particle Sciences focuses on emulsions, gels, particulates and drug/device
combination products with additional specialized capabilities in topical and
mucosal drug delivery. Through a full range of formulation, analytic, and
manufacturing services, Particle Sciences provides pharmaceutical companies
with a complete and seamless development solution that minimizes the time and
risk between discovery and the clinic. The company was founded in 1991 and is
headquartered in Bethlehem, Pennsylvania. Visit www.particlesciences.com,
email info@particlesciences.com or contact us at (610) 861-4701 for
information.

Contact: Maureen Cochran, 610-861-4701

SOURCE Particle Sciences Inc.

Maureen Cochran of Particle Sciences Inc., +1-610-861-4701